Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing nov...
Idera Pharmaceuticals is a clinical-stage bioph...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...
Following two acquisitions of Creagh Medical and NorMedix â recognized innovator...
Following two acquisitions of Creagh Medical an...
CHF Solutions is focused on improving the quality of life for patients suffering f...
CHF Solutions is focused on improving the quali...
We are a vertically integrated, clinical stage gene therapy company with four ongo...
We are a vertically integrated, clinical stage ...
Join the National Investor Network and get the latest information with your interests in mind.